NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report) shares rose 3.5% on Wednesday . The company traded as high as $19.38 and last traded at $19.38. Approximately 241 shares were traded during mid-day trading, a decline of 86% from the average session volume of 1,777 shares. The stock had previously closed at $18.72.
NewAmsterdam Pharma Stock Performance
The company’s 50-day moving average price is $22.11 and its 200 day moving average price is $22.04.
Hedge Funds Weigh In On NewAmsterdam Pharma
An institutional investor recently bought a new position in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. acquired a new position in NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 15,708 shares of the company’s stock, valued at approximately $397,000.
About NewAmsterdam Pharma
NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.
The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.
Further Reading
- Five stocks we like better than NewAmsterdam Pharma
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
